



# Ind-Swift Laboratories Ltd.

Regd. Off.: SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160 101  
CIN No.L24232CH1995PLC015553

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014

(₹ in Lacs)

PARTICULARS	QUARTER ENDED				YEAR ENDED
	30.06.2014	31.03.2014	30.06.2013	31.03.2014	
	Unaudited	Audited	Unaudited	Audited	
Income from Operations:					
(a) Net Sales/Incomes from Operations	18410.87	20989.87	24898.71	94066.15	
(b) Other Operating Income	450.41	381.95	420.72	1345.76	
<b>Total Net Sales / Operating Income</b>	<b>18861.28</b>	<b>21371.83</b>	<b>25319.43</b>	<b>95411.91</b>	
<b>Total Expenditure:</b>					
a. Cost of Materials Consumed	9017.78	10682.06	9929.56	44002.18	
b. Purchase of Stock-in-Trade	3085.41	5382.42	7243.45	23685.61	
c. (Increase) /decrease in FG, WIP & Stock-in-trade	381.67	4675.37	1003.96	6089.49	
d. Staff cost	1181.07	1160.91	1159.98	4666.13	
e. Depreciation	1812.52	1621.66	1520.09	6576.56	
f. Other expenditure	2277.14	5960.41	2530.30	12730.23	
<b>TOTAL</b>	<b>17755.59</b>	<b>29482.82</b>	<b>23387.35</b>	<b>97750.20</b>	
Profit/ (Loss) from Operations before Other Income, Interest & Exceptional Items	<b>1105.69</b>	<b>(8110.99)</b>	<b>1932.08</b>	<b>(2338.30)</b>	
Misc. Income	0.00	0.00	0.00	0.00	
<b>Profit/(Loss) before Interest &amp; Exceptional Items</b>	<b>1105.69</b>	<b>(8110.99)</b>	<b>1932.08</b>	<b>(2338.30)</b>	
Interest	2817.02	3205.67	2721.97	11982.32	
<b>Profit/(Loss) after Interest but before Exceptional Items</b>	<b>(1711.33)</b>	<b>(11316.66)</b>	<b>(789.89)</b>	<b>(14320.62)</b>	
Exceptional Items	0.00	0.00	0.00	0.00	
<b>Profit/(Loss) from Ordinary Activities before tax</b>	<b>(1711.33)</b>	<b>(11316.66)</b>	<b>(789.89)</b>	<b>(14320.62)</b>	
Provision for taxation	0.00	0.00	0.00	0.00	
Income Tax adjustment of Previous Year	0.19	0.88	0.00	(0.78)	
Mat Credit Entitlement	0.00	0.00	0.00	0.00	
Provision for deferred Tax	0.00	(2045.48)	0.00	(2045.48)	
<b>Net Profit/(Loss) from Ordinary Activities after tax</b>	<b>(1711.51)</b>	<b>(9272.05)</b>	<b>(789.89)</b>	<b>(12274.36)</b>	
Paid up Equity Share Capital (Face Value of Rs. 10/- per Share)	4096.32	4096.32	3927.05	4096.32	
Reserves excluding revaluation reserves	-	-	-	33791.26	
EPS (Rs.)					
Basic	(4.18)	(22.12)	(2.01)	(29.28)	
Diluted	(4.18)	(22.12)	(2.01)	(29.28)	
<b>PARTICULARS OF SHAREHOLDING</b>					
<b>Public Shareholding</b>					
Numbers of shares	19406344	19406344	19406344	19406344	
% of Shareholding	47.38	47.38	49.42	47.38	
<b>Promoters and Promoter group shareholding</b>					
<b>a) Pledged/Encumbered</b>					
- Number of Shares	19864126	19864126	19864126	19864126	
- Percentage of shares (as a % of total shareholding of promoter & promoters group)	92.15	92.15	100	92.15	
- Percentage of shares (as a % of total share capital of the Company)	48.49	48.49	50.58	48.49	
<b>b) Non-encumbered</b>					
- Number of Shares	1692725	1692725	Nil	1692725	
- Percentage of shares (as a % of total shareholding of promoter & promoters group)	7.85	7.85	Nil	7.85	
- Percentage of shares (as % of total share capital of the Company)	4.13	4.13	Nil	4.13	
<b>INVESTOR COMPLAINTS - QUARTER ENDED 30.06.2014</b>					
Pending at the beginning of the Quarter	NIL	Disposed off during the Quarter		NIL	
Received during the Quarter	NIL	Remaining unresolved at the end of the Quarter		NIL	
Notes:-					
1. During the quarter ended 30th June, 2014, the Company has achieved EBIDTA of Rs.30.36 Crores.					
2. Consequent to the enactment of the Companies Act, 2013 (the Act) and it's applicability for the accounting period commencing from 1st April, 2014, the Company is under the process of recalculating the remaining useful life of fixed assets in accordance with the provision of Schedule II of the Act. Accordingly, the impact on the change of the accounts of depreciation for the quarter ending 30th June, 2014 could not be ascertained.					
3. The Company is exclusively in the Pharmaceutical Business segment.					
4. The previous period figures have been re-grouped and re-arranged wherever necessary.					
5. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 12th August, 2014					
	For Ind-Swift Laboratories Limited				
	Sd/-				
	(N.R. Munjal)				
	Vice-Chairman cum Managing Director				
Place: Chandigarh					
Date: 12.08.2014					